Pay with

USD

Supports Visa, Mastercard, SEPA & more

Flexible trading, zero fees

Use your crypto for payments worldwide

Basic

Trade crypto freely

Magnify your profit with leverage

Convert & Auto-Invest

Trade any size with no fees and no slippage

Get exposure to leveraged positions simply

Pre-Market Trading

Trade new tokens before listing

Advanced

Trade on-chain with Gate Wallet

Smart access to new on-chain tokens

Smart strategies with automated trading

Follow expert trading strategies

CrossEx Trading

One margin balance, shared across platforms

Access hundreds of perpetual contracts

One platform for global traditional assets

Trade European-style vanilla options

Unified Account

Maximize your capital efficiency

Introduction to Futures Trading

Learn the basics of futures trading

Join events to earn rewards

Use virtual funds to practice risk-free trading

Stock CFD Derivatives

Access real US stocks and ETFs

Trade quality Hong Kong-listed stocks

Real Korean stocks and top assets

High leverage, 24/7 trading

Tokenized Stocks

Backed by real stock assets

Unlock full access to global stock IPOs

Mint GUSD for Treasury RWA yields

Stocks Activities

Trade Popular Stocks and Unlock Generous Airdrops

Launch

Collect candies to earn airdrops

Quick staking, earn potential new tokens

Hold GT and get massive airdrops for free

Unlock full access to global stock IPOs

Trade on-chain assets and earn airdrops

Earn futures points and claim airdrop rewards

Investment

Earn interest with idle tokens

Auto-invest on a regular basis

Dual Investment

Profit from market volatility

Earn rewards with flexible staking

Pledge one crypto to borrow another

One-stop lending hub

Premium wealth growth plans

Take control of your financial future

Top-tier quant strategies

Stake cryptos to earn in PoS products

No-liquidation leverage

Mint and Redeem Anytime, No Redemption Fees

Post, share, and explore crypto trends

Live crypto market analysis

Chat with crypto traders

What is happening in crypto

More

Promotions

Activity Center

Participate in activities to earn rewards

Invite friends to earn referral rewards

Affiliate Program

Earn exclusive commission rewards

Grow influence and earn airdrops

Real-time platform updates

Crypto industry articles

Huge fee discounts

Asset Management

One‑stop asset management solution

Enterprise digital asset solutions

Developers (API)

Connects to the Gate application ecosystem

OTC Bank Transfer

Deposit and withdraw fiat

Generous API rebate mechanisms

AI

Your all-in-one conversational AI partner

Use Gate AI directly in your social App

Gate Blue Lobster, ready to go

Gate for AI Agent

AI infrastructure, Gate MCP, Skills, and CLI

Gate Skills Hub

From office tasks to trading, the all-in-one skill hub makes AI even more useful.

Others

Find FAQs and help guides

Learn about crypto investing

Grow with the champions

Proof of Reserves

Gate promises 100% proof of reserves

Keep your assets secure

Australian entrepreneurs unveil AI-designed pet mRNA cancer vaccine process, involving 300GB of genetic data and multi-model collaboration.

2026-03-27 05:31:52

Gate News reports that on March 27, Paul Conyngham, the founder of an Australian AI consulting company, disclosed on the X platform the complete technical process of designing a personalized mRNA cancer vaccine for a pet dog using several AI chatbots. The dog was diagnosed with malignant mast cell cancer in May 2024, and approximately 300GB of data was obtained through whole-genome and RNA sequencing. With the collaboration of ChatGPT, Gemini, and Grok, target selection, protein structure modeling, and vaccine sequence design were completed, ultimately identifying a c-KIT gene mutation and selecting seven new antigen targets. The vaccine was prepared by a related research team at the University of New South Wales and administered at the University of Queensland's veterinary school. The overall treatment plan includes the combined use of the mRNA vaccine, tyrosine kinase inhibitors, and PD-1 inhibitors, with the administration schedule planned with AI assistance. Treatment began in December 2025, and within three months, some tumors showed shrinkage, but there remain unresponsive lesions that require surgical intervention. Experts note that this case represents an individual practice and does not yet constitute a universal medical conclusion.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Comment

0/400

No comments